If we close above cloud today, this ticker will hit all 4 entry conditions. OCUL historically has a 64.7% win rate and 1.62% average gain using this strategy.
OCUL OCUL has a pattern of descending triangles over the past 4-months (July-November 2019). The company launched its second commercial product Dextenza in the 2nd quarter where it gave away free samples. Its other product 'ReSure Sealent' has posted weak sales numbers ($472K in 1Q19 and ~600K in 2Q19). Dextenza is priced at $850 and is essentially an...
OCUL has had many difficulties over the past number of years, but finally, after shaking up management, getting over manufacturing and regulatory hurdles, and now receiving a broadened label and clarity on reimbursement the stock looks like a screaming buy. While it is always tricky to invest when a biopharma company is going through a product launch, it would...
Bearish head and shoulders setup. Most likely no sales. I will look to add after retracement. Potential AB=BC harmonic correction. Disclosure: I do not own shares of OCUL. This is not a note to buy or sell. please do your hw before investing.
Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline include Dextenza, OTX-TP, and OTX-TIC . The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA. SHORT...
yellow boxes are showing similar drop of price % retracement to 0.382 area possible, due to downtrendline and support in NOV 2017 additonally 3.3 would fill the gap 1. Price needs to break 3.0 level before confirmation 2. TP ist not huge but still approx 10 % at 3.30 area even 3.50 possible 3. SL i would set pretty tight at 2.85 area 4. we might see similar...
This channel is a mess , for the longer as I am. Is it to the end? Divergence on RSI and MACD let me think so , wait and see
There is a chance for as much as a 60% increase in as little as 37 days, based on T.A and news/rumors circling the company. The news around the company as well as dates for specific events to occur line up almost EXACTLY with what the T.A would lead me to believe.
There is a chance for as much as a 70% increase in as little as 22 days, based on T.A and news/rumors circling the company. The news around the company as well as dates for specific events to occur line up almost EXACTLY with what the T.A would lead me to believe.
Could potentially see as much as a 70% increase in as soon as the next 22 days huge buy opportunity, not just because of technical analysis but the news surrounding the company is almost EXACTLY in sync with where it looks to be going.
Resistence ahas been touched now it's time to restart , as you can see there is a bullish divergence on RSI
-the titile is moving on the bottom of a ascending channel -on daily is forming a double bottom
OCU was in our smart money watch list as it had Big insider buying on the 13th of August. It also seems forming a fallen angel formation. We think it has good upside potential. John sent an intraday text alert on August 14th while this was at $6.35 indicating a possible entry zone. This has continued to hold and is something we continue to like as a long idea.
OCUL: ocular therapeut 2018-07-19 08:00:14 Detected possible FDA approval
really great chart setup here. RSI heading up. MACD crossover. looking for uptrend from here on.